WSTNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
WEST PHARMACEUTICAL SERVICES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026
$383.91−0.11 (-0.03%)
Close on Oct 19, 2026
- Market cap
- $27.37B
- P/E (TTM)
- 49.2
- Dividend yield
- 0.22%
WEST PHARMACEUTICAL SERVICES INC revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q1 20 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proprietary Products | $2.73B | $2.62B | $2.49B | $2.44B | $2.40B | $2.34B | $2.33B | $2.31B | $2.32B | $2.37B | $2.40B | – | 81.9% | +13.7% |
| Contract-Manufactured Products | – | – | $582.00M | $573.70M | $562.10M | $557.80M | $558.70M | $562.10M | $561.50M | $554.90M | $552.50M | – | – | – |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q1 20 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proprietary Products | $766.00M | $715.80M | $657.20M | $629.80M | $612.80M | $582.10M | $577.80M | $579.10M | $602.50M | $665.70M | $710.10M | – | +25.0% |
| Corporate [Member] | – | – | – | – | – | – | – | – | – | – | – | -$67.90M | – |
| Contract-Manufactured Products | – | – | $63.40M | $69.80M | $69.30M | $68.70M | $72.30M | $74.90M | $74.10M | $71.80M | $72.10M | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of West Pharmaceutical Services's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.